Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Akorn, Inc. Issues FY 2012 Guidance; Revenue Guidance Below Analysts' Estimates
Akorn, Inc. announced that for fiscal 2012, it expects total revenue in the range of $210-220 million, GAAP net income in the range of $34-37 million, GAAP net income per diluted share in the range of $0.31-0.34, adjusted net income in the range of $46-49 million, adjusted net income per diluted share (EPS) in the range of $0.42-0.45 and adjusted EBITDA in the range of $85 million to $90 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $221 million, net income of $49 million, EPS of $0.45 and EBITDA of $87 million for fiscal 2012.
Latest Developments for Akorn Inc
Latest Key Developments in Pharmaceuticals
- AmerisourceBergen Corp Reaffirms FY 2013 EPS Gudiance-Conference Call
- Immunotec Inc Announces New CEO
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ
- Share this
- Link this
- Digg this


Follow Reuters